Catalyst

Slingshot members are tracking this event:

GlobalImmune Enrolling Patients in Phase 2 Study for GI-6301 Treatment of Chordoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GBIM

100%

Additional Information

Additional Relevant Details GlobalImmune is currently enrolling patients in its Phase 2 study of GI-6301 for the treatment of chrodoma.  The study expects to enroll 55 patients.  The study, sponsored by the National Cancer Institute, measures the difference in overall response rate among patients with Chordoma who are treated with radiation plus placebo vs. radiation plus vaccine.  
https://www.clinical...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 21, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Enrollment, Phase 2 Study, Gi-6301, Chordoma